Journal of Cancer Science and Research
Open Access

Bay Hematology Oncology, 8221 Teal Drive, Suite 302, Easton, Maryland, USA

Biography

Rodrigo Erlich  has been involved in many quantitative as well as qualitative studies; but her expertise are mostly related to qualitative and action research. Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, 306 Hualongqiao Road, Wenzhou, Zhejiang, P.R. China

Publications

• Case Report   
  Clinical Utility of Target Selector™ ctDNA Testing: Detection of EGFR Mutations via Liquid Biopsy Enabled Targeted Therapy Selection for Patients with Advanced NSCLC
  Author(s): Veena M Singh*, Rodrigo Erlich and Cecile Rose T Vibat
  
  Background: Molecular profiling of tumors provides information key for devising personalized therapeutic strategies for managing disease in cancer patients. A liquid biopsy is emerging as a sensitive means to evaluate biomarker status without the complications and costs associated with surgical biopsies, particularly for patients unable or unwilling to undergo invasive procedures. Materials and Methods: Patient blood specimens were collected in Biocept’s proprietary Blood Collection Tubes for liquid biopsy testing in Biocept’s CLIA-certified, CAP-accredited laboratory. Dual Circulating Tumor Cell (CTC) and circulating tumor DNA (ctDNA) platforms were utilized to detect ALK or ROS1 gene rearrangements by FISH, or EGFR mutations, respectively. Results: Described are three metastatic NSCLC patients for which liq.. View More»
  DOI: 10.4172/2576-1447.1000113

  Abstract HTML PDF